KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up.
KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up.
复制标题
DOI：
10.1002/pbc.29344
复制
发表时间：
2022-01
影响因子：
3.2
通讯作者：
中科院分区：
文献类型：
--
作者：
Twelve patients without therapy-related leukemia were studied after completing TOP2 poison chemotherapy in a high-risk neuroblastoma regimen. One patient harbored an inv(11) that was a KMT2A rearrangement. The KMT2A-MAML2 transcript was expressed at low level. The patient was prospectively followed. The inv(11) was undetectable in ensuing samples. Leukemia never developed after a 12.8-year follow-up period. Enriched etoposide-induced TOP2A cleavage in the relevant MAML2 genomic region supports a TOP2A DNA damage mechanism. After completing TOP2 poison chemotherapies, covert KMT2A-R clones may occur in a small minority of patients; however, not all KMT2A rearrangements herald a therapy-related leukemia diagnosis.
登录
查看更多内容
影响因子：
45.3
作者：
Cheung, Nai-Kong V.;Cheung, Irene Y.;Modak, Shakeel
通讯作者：
Modak, Shakeel
影响因子：
2.7
作者：
BUSQUE, L;ILARIA, R;GILLILAND, DG
通讯作者：
GILLILAND, DG
影响因子：
--
作者：
Colon, Nadja C;Chung, Dai H
通讯作者：
Chung, Dai H
影响因子：
3.8
作者：
Menu E;Beaufils N;Usseglio F;Balducci E;Lafage Pochitaloff M;Costello R;Gabert J
通讯作者：
Gabert J
影响因子：
45.3
作者：
Cheung, IY;Lo Piccolo, MS;Cheung, NKV
通讯作者：
Cheung, NKV